Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation.
Looking for a clinical trial? Visit us at www.withpower.com
All content for Power to the Patients is the property of Brandon Li and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation.
Looking for a clinical trial? Visit us at www.withpower.com
In this episode, Brandon Li sits down with Dr. Jordan Smoller - Jerrold F. Rosenbaum Chair in Psychiatry at Mass General, Co-Director for the Center for Suicide Research and Prevention at MGH and Harvard, Director of the Center for Precision Psychiatry, and a professor at Harvard Medical School, to explore the future of psychiatry. They discuss how AI, big data, and genomics are transforming mental health care—bringing us closer to precision psychiatry that moves beyond trial-and-error treatment.
Dr. Smoller shares his journey from early psychiatric research to leading one of the foremost centers in precision psychiatry, tackling some of the biggest challenges in mental health.
Key topics include:
The promise of precision psychiatry – Why psychiatry has lagged behind other fields in precision medicine, and how AI and genomics are closing the gap.
AI in suicide prevention – How electronic health records and machine learning models could predict suicide risk for earlier intervention.
Rethinking antidepressant treatment – Why 50% of patients don’t respond to their first antidepressant, and how predictive modeling could reduce trial-and-error prescribing.
Drug development breakthroughs – How genomics and AI are identifying new targets for psychiatric drug development and improving clinical trial success rates.
Digital tools & biomarkers – The role of wearables, vocal biomarkers, and real-world data in improving diagnosis, treatment selection, and monitoring.
Power to the Patients
Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation.
Looking for a clinical trial? Visit us at www.withpower.com